BR112014016076A8 - peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica - Google Patents
peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêuticaInfo
- Publication number
- BR112014016076A8 BR112014016076A8 BR112014016076A BR112014016076A BR112014016076A8 BR 112014016076 A8 BR112014016076 A8 BR 112014016076A8 BR 112014016076 A BR112014016076 A BR 112014016076A BR 112014016076 A BR112014016076 A BR 112014016076A BR 112014016076 A8 BR112014016076 A8 BR 112014016076A8
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- vector
- construction
- nucleic acid
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22062—Caspase-9 (3.4.22.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB11306784.7 | 2011-12-27 | ||
| EP11306784 | 2011-12-27 | ||
| PCT/EP2012/076968 WO2013098337A1 (en) | 2011-12-27 | 2012-12-27 | Cell-penetrating peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014016076A2 BR112014016076A2 (pt) | 2017-06-13 |
| BR112014016076A8 true BR112014016076A8 (pt) | 2017-07-04 |
| BR112014016076B1 BR112014016076B1 (pt) | 2022-03-15 |
Family
ID=47553033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014016076-7A BR112014016076B1 (pt) | 2011-12-27 | 2012-12-27 | Peptídeo, vetor, construção de peptídeo quimérico e composição farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9353155B2 (pt) |
| EP (1) | EP2797616B1 (pt) |
| JP (1) | JP6169606B2 (pt) |
| KR (1) | KR102071514B1 (pt) |
| CN (1) | CN104271147B (pt) |
| AU (1) | AU2012360845B2 (pt) |
| BR (1) | BR112014016076B1 (pt) |
| CA (1) | CA2859712C (pt) |
| DK (1) | DK2797616T3 (pt) |
| ES (1) | ES2748937T3 (pt) |
| IL (1) | IL233280B (pt) |
| PL (1) | PL2797616T3 (pt) |
| SG (2) | SG10201607271SA (pt) |
| WO (1) | WO2013098337A1 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2797617B1 (en) * | 2011-12-27 | 2020-01-22 | Sorbonne Université | Anti-tumor adjuvant therapy |
| EP3016972A2 (en) * | 2013-07-03 | 2016-05-11 | Université Pierre et Marie Curie (Paris 6) | Pro-apoptotic ras and raf peptides |
| EP2868326A1 (en) | 2013-11-04 | 2015-05-06 | Université Pierre et Marie Curie (Paris 6) | Peptide inhibitors of TEAD/YAP-TAZ interaction |
| EP2881472A1 (en) * | 2013-12-09 | 2015-06-10 | Université Pierre et Marie Curie (Paris 6) | A method of predicting a response to an anti-tumor treatment |
| JP6551825B2 (ja) * | 2014-02-10 | 2019-07-31 | 公立大学法人首都大学東京 | クロマチン構造制御剤 |
| CN105315348B (zh) * | 2014-06-23 | 2018-10-16 | 天津药物研究院 | 一种穿膜多肽及其制备方法和用途 |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| US20180066241A1 (en) * | 2015-03-31 | 2018-03-08 | Universite Pierre Et Marie Curie (Paris 6) | Pro-apoptotic set and pp2a peptides |
| CN105418733A (zh) * | 2015-06-23 | 2016-03-23 | 天津药物研究院有限公司 | 一种穿膜多肽与抗肿瘤药偶联物的制备及应用 |
| US10688153B2 (en) | 2015-11-06 | 2020-06-23 | The Board Of Trustees Of The University Of Illinois | Peptides and method for treatment of cardiac arrest |
| EP3272768A1 (en) * | 2016-07-22 | 2018-01-24 | Université Pierre et Marie Curie (Paris 6) | Chimeric peptides useful in malaria prophylaxis or treatment |
| WO2018114863A1 (en) | 2016-12-22 | 2018-06-28 | Sorbonne Universite | Cell penetrating peptides with improved internalization properties |
| US20200231642A1 (en) * | 2017-02-19 | 2020-07-23 | The National Institute for Biotechnology in the Negev Ltd. | Peptide kinase inhibitors and methods of use thereof |
| US11117930B2 (en) | 2017-02-23 | 2021-09-14 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| CN106995487B (zh) * | 2017-04-17 | 2019-12-03 | 扬州大学 | 源于鸡传染性贫血病毒VP1-aa 23-43多肽作为高效细胞穿膜肽的应用 |
| CN106831957B (zh) * | 2017-04-17 | 2019-12-03 | 扬州大学 | 一种源于鸡传染性贫血病毒VP1-aa 1-19多肽作为高效细胞穿膜肽的应用 |
| CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
| AU2018318319A1 (en) | 2017-08-18 | 2020-02-20 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| JP7072381B2 (ja) | 2017-12-21 | 2022-05-20 | 株式会社クボタ | コンバイン制御システム |
| CN111729070B (zh) * | 2020-06-02 | 2021-03-30 | 遵义医科大学珠海校区 | 多肽fl15在制备抗肿瘤药物中的应用 |
| WO2023017976A1 (ko) * | 2021-08-09 | 2023-02-16 | 주식회사 쎌트로이 | 양이온성 세포 투과성 펩타이드 및 이의 용도 |
| CN115028685B (zh) * | 2022-06-24 | 2023-10-20 | 张金强 | 一种阳离子双环抗菌肽及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468223A (en) | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
| FR2827866B1 (fr) * | 2001-07-27 | 2004-12-10 | Pasteur Institut | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations |
| WO2004011595A2 (fr) * | 2002-07-26 | 2004-02-05 | Institut Pasteur | Vecteurs destines au transfert de molecules d'interet dans des cellules cibles |
| WO2006124537A1 (en) * | 2005-05-12 | 2006-11-23 | The Burnham Institute | Compounds that regulate apoptosis |
| US20070184015A1 (en) | 2006-02-03 | 2007-08-09 | Soonkap Hahn | Novel PEGylation agent |
| CN101412747B (zh) * | 2008-10-21 | 2011-04-20 | 中国药科大学 | 新型穿膜肽及其用途 |
| EP2236603A1 (en) | 2009-03-30 | 2010-10-06 | Universite Pierre Et Marie Curie | Pro-apoptotic peptides |
| EP2797617B1 (en) * | 2011-12-27 | 2020-01-22 | Sorbonne Université | Anti-tumor adjuvant therapy |
-
2012
- 2012-12-27 JP JP2014549469A patent/JP6169606B2/ja active Active
- 2012-12-27 AU AU2012360845A patent/AU2012360845B2/en active Active
- 2012-12-27 DK DK12813376.6T patent/DK2797616T3/da active
- 2012-12-27 CA CA2859712A patent/CA2859712C/en active Active
- 2012-12-27 SG SG10201607271SA patent/SG10201607271SA/en unknown
- 2012-12-27 CN CN201280065370.2A patent/CN104271147B/zh active Active
- 2012-12-27 PL PL12813376T patent/PL2797616T3/pl unknown
- 2012-12-27 ES ES12813376T patent/ES2748937T3/es active Active
- 2012-12-27 EP EP12813376.6A patent/EP2797616B1/en active Active
- 2012-12-27 BR BR112014016076-7A patent/BR112014016076B1/pt active IP Right Grant
- 2012-12-27 WO PCT/EP2012/076968 patent/WO2013098337A1/en active Application Filing
- 2012-12-27 SG SG11201403683PA patent/SG11201403683PA/en unknown
- 2012-12-27 KR KR1020147021107A patent/KR102071514B1/ko active IP Right Grant
- 2012-12-27 US US14/366,199 patent/US9353155B2/en active Active
-
2014
- 2014-06-19 IL IL233280A patent/IL233280B/en active IP Right Grant
-
2016
- 2016-05-26 US US15/165,754 patent/US9644001B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2797616T3 (da) | 2019-10-07 |
| WO2013098337A1 (en) | 2013-07-04 |
| KR102071514B1 (ko) | 2020-01-30 |
| AU2012360845B2 (en) | 2017-05-11 |
| JP2015504050A (ja) | 2015-02-05 |
| IL233280B (en) | 2019-08-29 |
| EP2797616B1 (en) | 2019-07-31 |
| US20160257713A1 (en) | 2016-09-08 |
| CA2859712A1 (en) | 2013-07-04 |
| BR112014016076A2 (pt) | 2017-06-13 |
| SG10201607271SA (en) | 2016-10-28 |
| KR20140128971A (ko) | 2014-11-06 |
| JP6169606B2 (ja) | 2017-07-26 |
| ES2748937T3 (es) | 2020-03-18 |
| EP2797616A1 (en) | 2014-11-05 |
| CA2859712C (en) | 2023-09-19 |
| US9353155B2 (en) | 2016-05-31 |
| PL2797616T3 (pl) | 2020-03-31 |
| CN104271147A (zh) | 2015-01-07 |
| CN104271147B (zh) | 2018-01-12 |
| US20140364376A1 (en) | 2014-12-11 |
| AU2012360845A1 (en) | 2014-07-31 |
| IL233280A0 (en) | 2014-08-31 |
| SG11201403683PA (en) | 2014-10-30 |
| US9644001B2 (en) | 2017-05-09 |
| BR112014016076B1 (pt) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014016076A8 (pt) | peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica | |
| BR112013033350A2 (pt) | imunocitocina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| BR112012024287A2 (pt) | anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira | |
| BRPI1007005A2 (pt) | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 | |
| DK3578659T3 (da) | Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression | |
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
| BR112014021103A8 (pt) | anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014001991A2 (pt) | certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112014022788A2 (pt) | peptídeo, polipeptídeos, ácido nucleico, composição farmacêutica, conjugado e método in vitro | |
| BR112014012005A2 (pt) | composições, métodos, formulação farmacêutica e artigo | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013020368A2 (pt) | peptídeos modificados hidrofóbicos e uso dos mesmos para alvo específico no fígado | |
| CO7020907A2 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| BR112014010290A2 (pt) | composição farmacêutica, métodos, composições e usos | |
| BR112013030824A2 (pt) | bactéria gram-positiva, ácido necleico recombinante, composição farmacêutica e vetor | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112014017518A2 (pt) | anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo | |
| CO6970609A2 (es) | Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona | |
| BR112014004936A2 (pt) | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo | |
| BR112015011111A2 (pt) | proteína multifuncional e formulação farmacêutica | |
| BR112014005873A2 (pt) | enzimas, constructo de dna, vetor de expressão, célula, preparação, composição, uso e produto | |
| BR112013030395A2 (pt) | polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: INSTITUT CURIE (FR) ; SORBONNE UNIVERSITE (FR) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2012, OBSERVADAS AS CONDICOES LEGAIS. |